Therefore, the peptide-conjugated anti-miR21 drug selectively targets cells within the TME, including cancer cells, DCs, and macrophages that exhibit elevated levels of both PD-L1 and miR-21 expression, thus, eliciting remarkable antitumor effects. The gene discussed is CD274; the disease is cancer.